ADMA Biologics (NASDAQ:ADMA) stock observed trading -40.44% off 52-week high price. On the other end, the stock has been noted 46.88% away from low price over the last 52-weeks. The stock disclosed a move of -13.66% away from 50 day moving average and -12.19% away from 200 day moving average. Moving closer, we can see that shares have been trading -7.31% off 20-day moving average. It has market cap of $233.38M.
On Jan. 7, 2020, ADMA Biologics (NASDAQ:ADMA) a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and for the prevention of certain infectious diseases, released its entry into a 5-year manufacturing and supply agreement with an undisclosed partner to produce and sell plasma-derived intermediate fractions from ADMA’s U.S. Food and Drug Administration (FDA) approved Immune Globulin (IG) manufacturing process.
A core element of our business strategy is to leverage and maximize the revenue we generate from the available manufacturing capacity at our FDA-approved plasma-derived products production facility. Through the production of our own marketed assets, BIVIGAM®, ASCENIV™ and NABI-HB®, we will now be able to generate additional revenue over and above the sales of the FDA-approved drugs themselves, said Adam Grossman, ADMA’s President and Chief Executive Officer. Based on current production and forecasted market sales volumes, we estimate that these additional revenues from the sale of these fractions will add between $5 million and $10 million to our annual revenues for 2020 and 2021 respectively. Depending on future plant capacity utilization and potential expansion, as well as our forecasted IG production ramp, we believe this contract has the potential to generate between $10 million and $20 million per year from 2022 through 2024. We are proud to be an emerging partner of choice for plasma-derived intermediate fractions and we look forward to providing high quality products to this new partner and delivering the highest level of service and value to all of our customers to support our overall growth objectives.
The USA based company ADMA Biologics moved with change of 2.45% to $3.76 with the total traded volume of 867414 shares in recent session versus to an average volume of 660.46K shares. The stock was observed in the 5 days activity at -4.08%. The one month performance of stock was -8.96%. ADMA’s shares are at -8.07% for the quarter and driving a 19.75% return over the course of the past year and is now at -6.00% since this point in 2018. Right now the stock beta is 2.62. The average volatility for the week and month was at 4.98% and 4.38% respectively. There are 62.07M shares outstanding and 48.20M shares are floated in market.